Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Pharmaron Beijing Co., Ltd.
  6. News
  7. Summary
    300759   CNE100003JW4

PHARMARON BEIJING CO., LTD.

(300759)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Interim Period Ended June 30, 2021

07/15/2021 | 06:06pm EDT

Pharmaron Beijing Co., Ltd. provided earnings guidance for the interim period ended June 30, 2021. For the period, the company expects revenue to be in the range of RMB 3,114.2966 million to RMB 3,333.6132 million. Net profit attributable to owners of the parent is expected to be in the range of RMB 498.1186 million to RMB 593.9106 million. Basic earnings per share is expected to be in the range of RMB 0.6282 per share ­to RMB 0.7492 per share.


ę S&P Capital IQ 2021
All news about PHARMARON BEIJING CO., LTD.
10/20OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology..
CI
08/29Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2..
CI
07/15Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Interim Period Ended Jun..
CI
06/20PHARMARON BEIJING : Files for Hong Kong Bourse Listing of Renminbi, US Dollar Bonds
MT
06/09PHARMARON BEIJING : Proposes Reduction of Registered Capital
MT
06/08Pharmaron Beijing Raising $600 Million From Sale of Renminbi, US Dollar Convertible Bon..
MT
05/31Pharmaron Beijing Co., Ltd. Approves Cash Dividend for the Year 2020, Payable on 30 Jun..
CI
05/13MSCI Adds Ganfeng Lithium, Ningxia Baofeng to Global Emerging Markets Index Under Revam..
MT
04/30PHARMARON BEIJING : Closure of register of members for the first h shares class meeting of..
PU
04/29PHARMARON BEIJING : First Quarter Profit Rockets 142%, Revenue Soars
MT
More news
Financials
Sales 2021 7 212 M 1 127 M 1 127 M
Net income 2021 1 461 M 228 M 228 M
Net cash 2021 3 275 M 512 M 512 M
P/E ratio 2021 96,3x
Yield 2021 0,21%
Capitalization 135 B 21 076 M 21 056 M
EV / Sales 2021 18,2x
EV / Sales 2022 13,8x
Nbr of Employees -
Free-Float 71,1%
Chart PHARMARON BEIJING CO., LTD.
Duration : Period :
Pharmaron Beijing Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMARON BEIJING CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 177,44 CNY
Average target price 205,41 CNY
Spread / Average Target 15,8%
EPS Revisions
Managers and Directors
Bo Liang Lou Chairman & Chief Executive Officer
Shing Chung Li Chief Financial Officer & Board Secretary
Kexin Yang Chairman-Supervisory Board & Vice President
Hua Yang Chief Scientific Officer
Xiao Qiang Lou Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capi. (M$)
PHARMARON BEIJING CO., LTD.47.38%21 076
MODERNA, INC.226.29%137 595
LONZA GROUP AG32.74%61 065
IQVIA HOLDINGS INC.41.93%48 579
SEAGEN INC.-0.30%31 768
CELLTRION, INC.-39.00%25 528